Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand,
Drugs. 2015 Aug;75(12):1425-34. doi: 10.1007/s40265-015-0445-3.
Cangrelor (Kengrexal(®), Kengreal(™)) is an intravenously administered P2Y12 receptor inhibitor. It is direct-acting and reversible, with a very rapid onset and offset of action. The randomized, double-blind, multinational, phase III CHAMPION PHOENIX trial compared the efficacy of intravenous cangrelor with that of oral clopidogrel in patients requiring percutaneous coronary intervention (PCI) for stable angina pectoris, a non-ST-segment elevation acute coronary syndrome or ST-segment elevation myocardial infarction (MI). The primary composite efficacy endpoint of death from any cause, MI, ischaemia-drive revascularization or stent thrombosis in the 48 h following randomization occurred in significantly fewer cangrelor than clopidogrel recipients. The rate of severe or life-threatening non-coronary artery bypass graft-related, GUSTO-defined bleeding at 48 h did not significantly differ between cangrelor and clopidogrel recipients. In conclusion, intravenous cangrelor is an important new option for use in patients undergoing PCI who have not been treated with oral P2Y12 inhibitors.
坎格雷洛（Kengrexal(®)，Kengreal(™)）是一种静脉内给予的 P2Y12 受体抑制剂。它是直接作用和可逆转的，起效和失效非常迅速。这项随机、双盲、多中心、III 期 CHAMPION PHOENIX 试验比较了静脉内坎格雷洛与口服氯吡格雷在需要经皮冠状动脉介入治疗（PCI）的稳定型心绞痛、非 ST 段抬高型急性冠状动脉综合征或 ST 段抬高型心肌梗死（MI）患者中的疗效。在随机分组后 48 小时内，任何原因导致的死亡、心肌梗死、缺血驱动的血运重建或支架血栓形成的主要复合疗效终点在接受坎格雷洛治疗的患者中明显少于接受氯吡格雷治疗的患者。在 48 小时时，严重或危及生命的非冠状动脉旁路移植术相关、GUSTO 定义的出血在坎格雷洛和氯吡格雷治疗组之间没有显著差异。总之，对于未接受口服 P2Y12 抑制剂治疗的行 PCI 患者，静脉内坎格雷洛是一种重要的新选择。
